Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
helicobacter pylori vaccine · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | PLACEBO_COMPARATOR | - |
| 6 | EXPERIMENTAL | - |
| 7 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| helicobacter pylori vaccine | BIOLOGICAL | Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly |
| Placebo | BIOLOGICAL | Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly |
Inclusion Criteria: * Healthy * Ages 18-40 * Negative for H. pylori infection * Contraception for females Exclusion Criteria: * Present or past H. pylori infection * Medically significant gastroduodenal disease * Recent corticosteroid use * Bleed diathesis * Use of antibiotics used to treat H. py...
The Helicobacter pylori vaccine is an investigational vaccine being developed for the prevention of Helicobacter pylori infection, which is associated with conditions such as gastritis, gastric cancer, gastroduodenal ulcers, and lymphoma. It is currently in Phase 1 clinical development and has not been approved for use.
The Helicobacter pylori vaccine is being developed by Novartis AG, which trades under the ticker NVS. The vaccine is currently in Phase 1 clinical development and is not yet approved for commercial use.
The Helicobacter pylori vaccine is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the vaccine is not currently in active clinical trials.
The Helicobacter pylori vaccine has been studied in one completed Phase 1 clinical trial, identified as NCT00613665. This trial, titled 'Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults,' enrolled 113 participants in Germany and evaluated the vaccine's safety and immunogenicity.
The Helicobacter pylori vaccine is classified as a monoclonal antibody modality, though it is designed to prevent Helicobacter pylori infection. It is an investigational vaccine in Phase 1 clinical development and is not yet approved for use.